Find recruiting clinical trials for age-related macular degeneration (AMD) in the UK — including wet AMD, dry AMD, and geographic atrophy. See treatment pathways and where trials fit in.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Active neovascular disease
Standard: Intravitreal anti-VEGF injections (Aflibercept, Ranibizumab, Faricimab)
Less frequent dosing
Standard: Port delivery system, high-dose Aflibercept, or Faricimab
Geographic atrophy
Standard: Pegcetacoplan (Syfovre) or Avacincaptad (first GA treatments)
Abnormal blood vessels grow under the retina, causing rapid vision loss. Anti-VEGF injections can stop progression and often improve vision.
Gradual breakdown of the macula. More common but slower progression. Until recently there were no treatments — new complement inhibitors are changing this.
Advanced form of dry AMD with distinct areas of cell loss. The first treatments (Pegcetacoplan, Avacincaptad) were approved in 2023-2024.
Loading trials from ClinicalTrials.gov...
Standard anti-VEGF treatment starts with monthly loading doses (3 injections), then moves to every 4-12 weeks depending on response. Clinical trials are testing treatments requiring less frequent injections.
Yes. Pegcetacoplan (Syfovre) and Avacincaptad pegol are the first approved treatments for geographic atrophy (advanced dry AMD). Several other treatments are in clinical trials.
The port delivery system (Susvimo) is a small implant placed in the eye during surgery that continuously releases Ranibizumab. It reduces injection frequency from every 1-2 months to refill procedures every 6 months.
Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.
Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.